A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators

This is the Rustin study which was widely debated when presented at ASCO - the one key word in the conclusion (based on the abstract) is: "alone"